Multifaceted effects of hydroxychloroquine in human disease

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 2, 2013, Pages 264-272

  Olsen, Nancy J ^a   Schleich, Michele A ^a   Karp, David R ^b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Antimalarials; Apoptosis; Coagulopathy; Diabetes mellitus; Dyslipidemia; HIV infection; Hydroxychloroquine

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE; IMATINIB; LOW DENSITY LIPOPROTEIN RECEPTOR; METHOTREXATE; PHOSPHOLIPID ANTIBODY; PLACEBO; SALAZOSULFAPYRIDINE; ZIDOVUDINE;

ANTIGEN BINDING; APOPTOSIS; ARTICLE; AUTOPHAGY; BLOOD CLOTTING DISORDER; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN PROCESSING; RARE DISEASE; RECEPTOR UPREGULATION; RETINOPATHY; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; THROMBOSIS; THROMBOSIS PREVENTION;

ANTIMALARIALS; APOPTOSIS; COAGULOPATHY; DIABETES MELLITUS; DYSLIPIDEMIA; HIV INFECTION; HYDROXYCHLOROQUINE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84886093853     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.01.001     Document Type: Article

References (107)

1. Ruiz-Irastorza G., Khamashta M.A. Hydroxychloroquine: the cornerstone of lupus therapy. Lupus 2008, 17(4):271-273.
2. Lee S.J., Silverman E., Bargman J.M. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol 2011, 7(12):718-729.
3. O'Dell J.R., Leff R., Paulsen G., Haire C., Mallek J., Eckhoff P.J., et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46(5):1164-1170.
4. Moreland L.W., O'Dell J.R., Paulus H.E., Curtis J.R., Bathon J.M., Clair E.W., et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum 2012, 64(9):2824-2835.
5. Dubois E.L. Antimalarials in the management of discoid and systemic lupus erythematosus. Semin Arthritis Rheum 1978, 8(1):33-51.
6. Ikeda T., Kanazawa N., Furukawa F. Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study. J Dermatol 2012, 39(6):531-535.
7. Pons-Estel G.J., Alarcón G.S., González L.A., Zhang J., Vilá L.M., Reveille J.D., et al. Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort. Arthritis Care Res (Hoboken) 2010, 62(3):393-400.
8. Arnal C., Piette J.C., Léone J., Taillan B., Hachulla E., Roudot-Thoraval F., et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 2002, 29(1):75-83.
9. Pons-Estel G.J., Alarcón G.S., McGwin G., Danila M.I., Zhang J., Bastian H.M., et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 2009, 61(6):830-839.
10. Sisó A., Ramos-Casals M., Bové A., Brito-Zerón P., Soria N., Muñoz S., et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 2008, 17(4):281-288.
11. Kasitanon N., Fine D.M., Haas M., Magder L.S., Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006, 15(6):366-370.
12. Alarcón G.S., McGwin G., Bertoli A.M., Fessler B.J., Calvo-Alén J., Bastian H.M., et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007, 66(9):1168-1172.
13. Fessler B.J., Alarcón G.S., McGwin G., Roseman J., Bastian H.M., Friedman A.W., et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005, 52(5):1473-1480.
14. Molad Y., Gorshtein A., Wysenbeek A.J., Guedj D., Majadla R., Weinberger A., et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 2002, 11(6):356-361.
15. Ruiz-Irastorza G., Olivares N., Ruiz-Arruza I., Martinez-Berriotxoa A., Egurbide M.V., Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009, 11(4):R109.
16. James J.A., Kim-Howard X.R., Bruner B.F., Jonsson M.K., McClain M.T., Arbuckle M.R., et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 2007, 16(6):401-409.
17. Tsakonas E., Joseph L., Esdaile J.M., Choquette D., Senécal J.L., Cividino A., et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998, 7(2):80-85.
18. The Canadian Hydroxychloroquine Study Group A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991, 324(3):150-154.
19. Izmirly P.M., Kim M.Y., Llanos C., Le P.U., Guerra M.M., Askanase A.D., et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010, 69(10):1827-1830.
20. Izmirly P.M., Costedoat-Chalumeau N., Pisoni C.N., Khamashta M.A., Kim M.Y., Saxena A., et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012, 126(1):76-82.
21. Gasparyan A.Y., Ayvazyan L., Cocco G., Kitas G.D. Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des 2012, 18(11):1543-1555.
22. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996, 25(4):191-193.
23. Ardoin S.P., Sandborg C., Schanberg L.E. Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. Lupus 2007, 16(8):618-626.
24. Costedoat-Chalumeau N., Leroux G., Piette J.C., Amoura Z. Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment?. Joint Bone Spine 2010, 77(1):4-5.
25. Wallace D.J., Linker-Israeli M., Metzger A.L., Stecher V.J. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 1993, 2(Suppl. 1):S13-S15.
26. Gaujoux-Viala C., Smolen J.S., Landewé R., Dougados M., Kvien T.K., Mola E.M., et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010, 69(6):1004-1009.
27. Pavelka K., Sen K.P., Pelísková Z., Vácha J., Trnavský K. Hydroxychloroquine sulphate in the treatment of rheumatoid arthritis: a double blind comparison of two dose regimens. Ann Rheum Dis 1989, 48(7):542-546.
28. O'Dell J.R., Blakely K.W., Mallek J.A., Eckhoff P.J., Leff R.D., Wees S.J., et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001, 44(10):2235-2241.
29. Nuver-Zwart I.H., van Riel P.L., van de Putte L.B., Gribnau F.W. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. Ann Rheum Dis 1989, 48(5):389-395.
30. Saunders S.A., Capell H.A., Stirling A., Vallance R., Kincaid W., McMahon A.D., et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 2008, 58(5):1310-1317.
31. Costedoat-Chalumeau N., Amoura Z., Hulot J.S., Hammoud H.A., Aymard G., Cacoub P., et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006, 54(10):3284-3290.
32. Ruiz-Irastorza G., Egurbide M.V., Pijoan J.I., Garmendia M., Villar I., Martinez-Berriotxoa A., et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006, 15(9):577-583.
33. Shinjo S.K., Bonfá E., Wojdyla D., Borba E.F., Ramirez L.A., Scherbarth H.R., et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 2010, 62(3):855-862.
34. Francès C., Cosnes A., Duhaut P., Zahr N., Soutou B., Ingen-Housz-Oro S., et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 2012, 148(4):479-484.
35. Ramos-Casals M., Tzioufas A.G., Stone J.H., Sisó A., Bosch X. Treatment of primary Sjögren syndrome: a systematic review. J Am Med Assoc 2010, 304(4):452-460.
36. White N.J., Miller K.D., Marsh K., Berry C.D., Turner R.C., Williamson D.H., et al. Hypoglycaemia in African children with severe malaria. Lancet 1987, 1(8535):708-711.
37. Cansu D.U., Korkmaz C. Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. Rheumatology (Oxford) 2008, 47(3):378-379.
38. Unübol M., Ayhan M., Guney E. Hypoglycemia induced by hydroxychloroquine in a patient treated for rheumatoid arthritis. J Clin Rheumatol 2011, 17(1):46-47.
39. Winter E.M., Schrander-van der Meer A., Eustatia-Rutten C., Janssen M. Hydroxychloroquine as a glucose lowering drug. BMJ Case Rep 2011, bcr0620114393.
40. Shojania K., Koehler B.E., Elliott T. Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. J Rheumatol 1999, 26(1):195-196.
41. Kang L., Mikuls T.R., O'Dell J.R. Hydroxychloroquine: a diabetic drug in disguise?. BMJ Case Rep 2009.
42. Quatraro A., Consoli G., Magno M., Caretta F., Nardozza A., Ceriello A., et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug?. Ann Intern Med 1990, 112(9):678-681.
43. Gerstein H.C., Thorpe K.E., Taylor D.W., Haynes R.B. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas-a randomized trial. Diabetes Res Clin Pract 2002, 55(3):209-219.
44. Powrie J.K., Smith G.D., Shojaee-Moradie F., Sönksen P.H., Jones R.H. Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus. Am J Physiol 1991, 260(6 Pt 1):E897-904.
45. Wasko M.C., Hubert H.B., Lingala V.B., Elliott J.R., Luggen M.E., Fries J.F., et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. J Am Med Assoc 2007, 298(2):187-193.
46. Bili A., Sartorius J.A., Kirchner H.L., Morris S.J., Ledwich L.J., Antohe J.L., et al. Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. J Clin Rheumatol 2011, 17(3):115-120.
47. Penn S.K., Kao A.H., Schott L.L., Elliott J.R., Toledo F.G., Kuller L., et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2010, 37(6):1136-1142.
48. Rekedal L.R., Massarotti E., Garg R., Bhatia R., Gleeson T., Lu B., et al. Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. Arthritis Rheum 2010, 62(12):3569-3573.
49. Solomon D.H., Massarotti E., Garg R., Liu J., Canning C., Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. J Am Med Assoc 2011, 305(24):2525-2531.
50. Mercer E., Rekedal L., Garg R., Lu B., Massarotti E.M., Solomon D.H. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res Ther 2012, 14(3):R135.
51. Blazar B.R., Whitley C.B., Kitabchi A.E., Tsai M.Y., Santiago J., White N., et al. In vivo chloroquine-induced inhibition of insulin degradation in a diabetic patient with severe insulin resistance. Diabetes 1984, 33(12):1133-1137.
52. Contreres J.O., Faure R., Baquiran G., Bergeron J.J., Posner B.I. ATP-dependent desensitization of insulin binding and tyrosine kinase activity of the insulin receptor kinase. The role of endosomal acidification. J Biol Chem 1998, 273(34):22007-22013.
53. Razani B., Feng C., Semenkovich C.F. p53 is required for chloroquine-induced atheroprotection but not insulin sensitization. J Lipid Res 2010, 51(7):1738-1746.
54. Wallace D.J. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?. Arthritis Rheum 1987, 30(12):1435-1436.
55. Ernst E., Rose M., Lee R. Modification of transoperative changes in blood fluidity by hydroxychloroquine: a possible explanation for the drug's antithrombotic effect. Pharmatherapeutica 1984, 4(1):48-52.
56. Johansson E., Forsberg K., Johnsson H. Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement. Haemostasis 1981, 10(2):89-96.
57. Johnson R., Charnley J. Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty. Clin Orthop Relat Res 1979, 144:174-177.
58. Ruiz-Irastorza G., Ramos-Casals M., Brito-Zeron P., Khamashta M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010, 69(1):20-28.
59. Ho K.T., Ahn C.W., Alarcón G.S., Baethge B.A., Tan F.K., Roseman J., et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 2005, 44(10):1303-1307.
60. Kaiser R., Cleveland C.M., Criswell L.A. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009, 68(2):238-241.
61. Jung H., Bobba R., Su J., Shariati-Sarabi Z., Gladman D.D., Urowitz M., et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010, 62(3):863-868.
62. Prowse C., Pepper D., Dawes J. Prevention of the platelet alpha-granule release reaction by membrane-active drugs. Thromb Res 1982, 25(3):219-227.
63. Espinola R.G., Pierangeli S.S., Gharavi A.E., Harris E.N., Ghara A.E. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002, 87(3):518-522.
64. Rand J.H., Wu X.X., Quinn A.S., Chen P.P., Hathcock J.J., Taatjes D.J. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 2008, 112(5):1687-1695.
65. Rand J.H., Wu X.X., Quinn A.S., Ashton A.W., Chen P.P., Hathcock J.J., et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010, 115(11):2292-2299.
66. Toubi E., Kessel A., Rosner I., Rozenbaum M., Lorber M., Paran D., et al. Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE. Lupus 2003, 12(4):297-301.
67. Broder A, Putterman C. Hydroxychloroquine se is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. J Rheumatol. 2013;40(1):30-33.
68. Mirjafari H., Al-Husain A., Bruce I.N. Cardiovascular risk factors in inflammatory arthritis. Curr Opin Lipidol 2011, 22(4):296-301.
69. Petri M., Lakatta C., Magder L., Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994, 96(3):254-259.
70. Rahman P., Gladman D.D., Urowitz M.B., Yuen K., Hallett D., Bruce I.N. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999, 26(2):325-330.
71. Hodis H.N., Quismorio F.P., Wickham E., Blankenhorn D.H. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993, 20(4):661-665.
72. Kavanaugh A., Adams-Huet B., Jain R., Denke M., McFarlin J. Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus. J Clin Rheumatol 1997, 3(1):3-8.
73. Cairoli E., Rebella M., Danese N., Garra V., Borba E. Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus 2012, 21(11):1178-1182.
74. Munro R., Morrison E., McDonald A.G., Hunter J.A., Madhok R., Capell H.A. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997, 56(6):374-377.
75. Morris S.J., Wasko M.C., Antohe J.L., Sartorius J.A., Kirchner H.L., Dancea S., et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2011, 63(4):530-534.
76. Sachet J.C., Borba E.F., Bonfá E., Vinagre C.G., Silva V.M., Maranhão R.C. Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 2007, 16(4):273-278.
77. Rossoni C., Bisi M.C., Keiserman M.W., Staub H.L. Antimalarials and cholesterol profile of patients with systemic lupus erythematosus. Rev Bras Reumatol 2011, 51(4):383-387.
78. Tam L.S., Li E.K., Lam C.W., Tomlinson B. Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease. Lupus 2000, 9(6):413-416.
79. Park Y.B., Choi H.K., Kim M.Y., Lee W.K., Song J., Kim D.K., et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002, 113(3):188-193.
80. van Halm V.P., Nurmohamed M.T., Twisk J.W., Dijkmans B.A., Voskuyl A.E. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006, 8(5):R151.
81. Sperber K., Louie M., Kraus T., Proner J., Sapira E., Lin S., et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther 1995, 17(4):622-636.
82. Sperber K., Chiang G., Chen H., Ross W., Chusid E., Gonchar M., et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther 1997, 19(5):913-923.
83. Piconi S., Parisotto S., Rizzardini G., Passerini S., Terzi R., Argenteri B., et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011, 118(12):3263-3272.
84. Paton N.I., Aboulhab J. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. HIV Med 2005, 6(1):13-20.
85. Aguirre-Cruz L., Torres K.J., Jung-Cook H., Fortuny C., Sánchez E., Soda-Mehry A., et al. Short communication: preferential concentration of hydroxychloroquine in adenoid tissue of HIV-infected subjects. AIDS Res Hum Retroviruses 2010, 26(3):339-342.
86. Savarino A., Gennero L., Sperber K., Boelaert J.R. The anti-HIV-1 activity of chloroquine. J Clin Virol 2001, 20(3):131-135.
87. Rolain J.M., Colson P., Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 2007, 30(4):297-308.
88. Chiang G., Sassaroli M., Louie M., Chen H., Stecher V.J., Sperber K. Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. Clin Ther 1996, 18(6):1080-1092.
89. Savarino A., Gennero L., Chen H.C., Serrano D., Malavasi F., Boelaert J.R., et al. Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS 2001, 15(17):2221-2229.
90. Ashfaq U.A., Javed T., Rehman S., Nawaz Z., Riazuddin S. Lysosomotropic agents as HCV entry inhibitors. Virol J 2011, 8:163.
91. Ruiz-Irastorza G., Ugarte A., Egurbide M.V., Garmendia M., Pijoan J.I., Martinez-Berriotxoa A., et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 2007, 66(6):815-817.
92. Sotelo J., Briceño E., López-González M.A. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006, 144(5):337-343.
93. Mukhopadhyay A., Helgason G.V., Karvela M., Holyoake T.L. Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon?. Expert Rev Hematol 2011, 4(4):369-371.
94. Mansilla E., Marin G.H., Nuñez L., Drago H., Sturla F., Mertz C., et al. The lysosomotropic agent, hydroxychloroquine, delivered in a biodegradable nanoparticle system, overcomes drug resistance of B-chronic lymphocytic leukemia cells in vitro. Cancer Biother Radiopharm 2010, 25(1):97-103.
95. Rahim R., Strobl J.S. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs 2009, 20(8):736-745.
96. Fernandez Y., Ramakrishnan R., Rathinavelu A. Effect of systemic lupus erythematosus (SLE) treatment drugs on GI-101A breast tumor cell growth. Life Sci 2000, 67(5):567-575.
97. Lagneaux L., Delforge A., Carlier S., Massy M., Bernier M., Bron D. Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors. Br J Haematol 2001, 112(2):344-352.
98. Lagneaux L., Delforge A., Dejeneffe M., Massy M., Bernier M., Bron D. Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio. Leuk Lymphoma 2002, 43(5):1087-1095.
99. Lai J.H., Ho L.J., Lu K.C., Chang D.M., Shaio M.F., Han S.H. Western and Chinese antirheumatic drug-induced T cell apoptotic DNA damage uses different caspase cascades and is independent of Fas/Fas ligand interaction. J Immunol 2001, 166(11):6914-6924.
100. Meng X.W., Feller J.M., Ziegler J.B., Pittman S.M., Ireland C.M. Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine. Arthritis Rheum 1997, 40(5):927-935.
101. Liu S.T., Wang C.R., Yin G.D., Liu M.F., Lee G.L., Chen M.Y., et al. Hydroxychloroquine sulphate inhibits in vitro apoptosis of circulating lymphocytes in patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol 2001, 19(1):29-35.
102. Meng X.W., Fraser M.J., Feller J.M., Ziegler J.B. Caspase-3-dependent and caspase-3-independent pathways leading to chromatin DNA fragmentation in HL-60 cells. Apoptosis 2000, 5(1):61-67.
103. Boya P., Gonzalez-Polo R.A., Poncet D., Andreau K., Vieira H.L., Roumier T., et al. Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene 2003, 22(25):3927-3936.
104. Kim W.U., Yoo S.A., Min S.Y., Park S.H., Koh H.S., Song S.W., et al. Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes. Clin Exp Immunol 2006, 144(3):503-511.
105. Wolfe F., Marmor M.F. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010, 62(6):775-784.
106. Kuznik A., Bencina M., Svajger U., Jeras M., Rozman B., Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011, 186(8):4794-4804.
107. Goldman F.D., Gilman A.L., Hollenback C., Kato R.M., Premack B.A., Rawlings D.J. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 2000, 95(11):3460-3466.